Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ALKEM LABORATORIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-23 |
ADCOCK INGRAM Jun-14 |
ALKEM LABORATORIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,625 | 320 | - | |
Low | Rs | 2,835 | 231 | - | |
Sales per share (Unadj.) | Rs | 970.1 | 95.1 | - | |
Earnings per share (Unadj.) | Rs | 84.2 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 110.2 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 50.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 756.4 | 74.6 | - | |
Shares outstanding (eoy) | m | 119.57 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.3 | 2.9 | 115.1% | |
Avg P/E ratio | x | 38.4 | -11.5 | -334.1% | |
P/CF ratio (eoy) | x | 29.3 | -13.9 | -211.6% | |
Price / Book Value ratio | x | 4.3 | 3.7 | 115.8% | |
Dividend payout | % | 59.4 | 0 | - | |
Avg Mkt Cap | Rs m | 386,207 | 46,446 | 831.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 21,314 | 2,915 | 731.2% | |
Avg. sales/employee | Rs Th | 0 | 3,739.2 | - | |
Avg. wages/employee | Rs Th | 0 | 679.0 | - | |
Avg. net profit/employee | Rs Th | 0 | -942.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 115,993 | 16,052 | 722.6% | |
Other income | Rs m | 2,161 | 112 | 1,922.2% | |
Total revenues | Rs m | 118,153 | 16,165 | 730.9% | |
Gross profit | Rs m | 15,065 | -2,782 | -541.5% | |
Depreciation | Rs m | 3,104 | 693 | 448.1% | |
Interest | Rs m | 1,074 | 435 | 246.9% | |
Profit before tax | Rs m | 13,048 | -3,797 | -343.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,980 | 237 | 1,255.8% | |
Profit after tax | Rs m | 10,068 | -4,045 | -248.9% | |
Gross profit margin | % | 13.0 | -17.3 | -74.9% | |
Effective tax rate | % | 22.8 | -6.2 | -365.5% | |
Net profit margin | % | 8.7 | -25.2 | -34.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 86,064 | 11,757 | 732.0% | |
Current liabilities | Rs m | 37,071 | 6,615 | 560.4% | |
Net working cap to sales | % | 42.2 | 32.0 | 131.9% | |
Current ratio | x | 2.3 | 1.8 | 130.6% | |
Inventory Days | Days | 33 | 111 | 29.4% | |
Debtors Days | Days | 67 | 124 | 54.1% | |
Net fixed assets | Rs m | 37,245 | 6,853 | 543.5% | |
Share capital | Rs m | 239 | 75 | 320.8% | |
Net worth | Rs m | 90,447 | 12,599 | 717.9% | |
Long term debt | Rs m | 0 | 4,428 | 0.0% | |
Total assets | Rs m | 124,541 | 23,801 | 523.3% | |
Interest coverage | x | 13.2 | -7.7 | -170.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 138.1% | |
Return on assets | % | 8.9 | -15.2 | -59.0% | |
Return on equity | % | 11.1 | -32.1 | -34.7% | |
Return on capital | % | 15.6 | -19.8 | -78.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,825 | 1,370 | 1,227.9% | |
From Investments | Rs m | 1,128 | -421 | -268.2% | |
From Financial Activity | Rs m | -17,608 | 4,018 | -438.2% | |
Net Cashflow | Rs m | 416 | 4,968 | 8.4% |
Compare ALKEM LABORATORIES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ALKEM LABORATORIES With: ALBERT DAVID SUVEN LIFE SCIENCES STRIDES PHARMA SCIENCE VIVIMED LABS BH.IMMUN&BIO
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.